Plasma Fractionation Market Dynamics Driven by Expansion in Therapeutic Applications Including Neurology Immunology Hematology Critical Care and Pulmonology

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Plasma Fractionation Market- (By Product (Immune-Globulins(Intravenous Immune-Globulins, Subcutaneous Immune-Globulins, Other Immune-Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Others), Albumin, Protease Inhibitors, Other Plasma Products), By Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato-Oncology, Rheumatology, Others), By End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Plasma Fractionation Market is valued at USD 4.2 Bn in 2023, and it is expected to reach USD 8.9 Bn by the year 2031 with a CAGR of 10.1% during a forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2140

Plasma fractionation is a specialized process involving the separation and isolation of specific components from plasma-the liquid portion of blood-to produce therapeutically significant products, including albumin, immunoglobulins, and clotting factors. These plasma-derived therapies play a critical role in the treatment and management of numerous medical conditions, particularly those related to immune deficiencies and rare disorders.

The global plasma fractionation market is witnessing substantial growth, driven largely by the increasing aging population, which exhibits a higher prevalence of chronic and rare diseases necessitating plasma-based interventions. Rising demand for immunoglobulins and alpha-1 antitrypsin across multiple therapeutic applications is further contributing to market expansion. The growing network of plasma collection centers worldwide is enhancing the efficiency and capacity of the supply chain. Moreover, government-led initiatives promoting awareness of the clinical value of plasma-derived therapies are expected to support sustained growth throughout the forecast period.

Prominent Players in the Plasma Fractionation Market:
• CSL (Australia)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols, S.A. (Spain)
• Octapharma AG (Switzerland)
• Kedrion S.P.A (Italy)
• LFB (France)
• ADMA Biologics (US)
• Sanquin (Netherlands)
• China Biologic Products Holdings Inc. (China)
• GC Pharma (Korea)
• Hualan Bioengineering Co., Ltd. (China)
• Japan Blood Products Organization (Japan)
• Emergent BioSolutions (US)
• Shanghai Raas Blood Products Co., Ltd. (China)
• Intas Pharmaceuticals Ltd. (India)
• Bharat Serum Vaccines Limited (India)
• SK Plasma (Korea)
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
• Kamada (Israel)
• Centurion Pharma (Istanbul)
• Prothya Biosolutions (Netherlands)
• PlasmaGen BioSciences Pvt. Ltd. (India)
• Virchow Biotech Private Limited (India)
• Fusion Healthcare (India)
• Hemarus Therapeutics Limited (India)
• Others

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Market Dynamics
Drivers:
The rising prevalence of immunodeficiency disorders is a primary driver of the plasma fractionation market. Globally, the increasing demand for plasma-derived therapies-particularly immunoglobulins-is fueling market growth. In response, leading industry participants are intensifying research and development efforts to introduce innovative plasma-based treatments. Additionally, strategic investments and acquisitions of plasma collection centers are being undertaken to strengthen supply chain resilience and ensure consistent access to raw plasma resources. The ongoing global increase in immunodeficiency conditions continues to sustain demand for these therapies.

Challenges:
The growing adoption of recombinant therapies poses a significant challenge to the plasma fractionation market. Recombinant products are gaining prominence due to their lower immunogenicity and effectiveness in prophylactic treatment settings. These therapies offer advantages such as extended half-life, reduced dosing frequency, and improved preventive outcomes. As a result, the increasing clinical preference for recombinant alternatives is gradually limiting the uptake of traditional plasma-derived treatments.

Regional Trends:
The Asia-Pacific region is projected to capture a substantial share of the plasma fractionation market, with robust growth expected over the forecast period. This growth is supported by the active presence of key industry players engaged in the development and commercialization of advanced plasma-based therapies. Simultaneously, North America-particularly the United States-is poised for continued market expansion, underpinned by a well-established plasma fractionation infrastructure that supports regional production capacity and overall market performance.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2140

Recent Developments:
• In March 2023, Takeda made an investment of 100 billion JPY in the establishment of a novel manufacturing facility in Japan, specifically dedicated to the production of plasma-derived medicines. The investment made by Takeda exemplified the company's dedication to prioritising patients and fulfilling its obligations in relation to its patient-centric, people-oriented, and environmentally conscious objectives. This approach was supported by the utilisation of data and digital technologies.
• In Dec 2022, CSL has recently inaugurated its Plasma Fractionation Facility in Victoria, Australia, which represents a significant milestone in the country's plasma manufacturing sector. With a staggering investment of $900 Bn, this state-of-the-art facility stands as the largest of its type in the Southern Hemisphere. The aforementioned statement pertains to a capital investment programme of over $2 billion that CSL is presently implementing in Australia.

Segmentation of Plasma Fractionation Market-
By Product-
• Immune-Globulins
o Intravenous Immune-Globulins
o Subcutaneous Immune-Globulins
o Other Immune-Globulins
• Coagulation Factor Concentrates
o Factor VIII
o Factor IX
o Von Willebrand Factor
o Prothrombin Complex Concentrate
o Fibrinogen Concentrates
o Factor XIII
o Others
• Albumin
• Protease Inhibitors
• Other Plasma Products
By Application-
• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Hemato-Oncology
• Rheumatology
• Others
By End-User-
• Hospitals & Clinics
• Clinical Research Laboratories
• Academic Institutes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/plasma-fractionation-market/2140

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.